Hansoh Pharma Reports Positive Phase 2 Results for HS-20089 in Platinum-Resistant Ovarian Cancer

Reuters

Oct 20

Hansoh Pharma Reports Positive Phase 2 Results for HS-20089 in Platinum-Resistant Ovarian Cancer

Hansoh Pharmaceutical Group Co., Ltd. has announced positive phase 2 clinical trial results for HS-20089, a B7-H4-targeted antibody-drug conjugate $(ADC)$, in patients with platinum-resistant ovarian cancer $(PROC)$. The findings were presented in a poster session at the European Society for Medical Oncology (ESMO) 2025 Annual Meeting and will be featured in an oral presentation at the IGCS 2025 Annual Global Meeting in Cape Town, South Africa. HS-20089 (licensed to GSK as GSK5733584) demonstrated a confirmed objective response rate $(ORR)$ of 48.5%, a duration of response (DoR) of 6.8 months, a median progression-free survival (mPFS) of 6.4 months, and a median overall survival (mOS) of 14.6 months at a dose of 4.8 mg/kg. The safety profile was manageable, consistent with phase 1 data, and no new safety signals were observed. The phase 2 study included heavily pretreated PROC patients regardless of tumor B7-H4 expression. A phase 3 study of HS-20089 is currently ongoing (NCT06855069).

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Hansoh Pharmaceutical Group Co. Ltd. published the original content used to generate this news brief on October 20, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2576019002"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2576019002\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2576019002?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-20 08:17","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2576019002","market":"fut","top_or_hot":-1,"title":"Hansoh Pharma Reports Positive Phase 2 Results for HS-20089 in Platinum-Resistant Ovarian Cancer","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Hansoh Pharma Reports Positive Phase 2 Results for HS-20089 in Platinum-Resistant Ovarian Cancer\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Hansoh Pharmaceutical Group Co., Ltd. has announced positive phase 2 clinical trial results for HS-20089, a B7-H4-targeted antibody-drug conjugate <a href=\"https://laohu8.com/S/ADC\">$(ADC)$</a>, in patients with platinum-resistant ovarian cancer <a href=\"https://laohu8.com/S/PROC\">$(PROC)$</a>. The findings were presented in a poster session at the European Society for Medical Oncology (ESMO) 2025 Annual Meeting and will be featured in an oral presentation at the IGCS 2025 Annual Global Meeting in Cape Town, South Africa. HS-20089 (licensed to GSK as GSK5733584) demonstrated a confirmed objective response rate <a href=\"https://laohu8.com/S/ORR\">$(ORR)$</a> of 48.5%, a duration of response (DoR) of 6.8 months, a median progression-free survival (mPFS) of 6.4 months, and a median overall survival (mOS) of 14.6 months at a dose of 4.8 mg/kg. The safety profile was manageable, consistent with phase 1 data, and no new safety signals were observed. The phase 2 study included heavily pretreated PROC patients regardless of tumor B7-H4 expression. A phase 3 study of HS-20089 is currently ongoing (NCT06855069).\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Hansoh Pharmaceutical Group Co. Ltd. published the original content used to generate this news brief on October 20, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Hansoh Pharma Reports Positive Phase 2 Results for HS-20089 in Platinum-Resistant Ovarian Cancer</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHansoh Pharma Reports Positive Phase 2 Results for HS-20089 in Platinum-Resistant Ovarian Cancer\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-10-20 08:17</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Hansoh Pharma Reports Positive Phase 2 Results for HS-20089 in Platinum-Resistant Ovarian Cancer\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Hansoh Pharmaceutical Group Co., Ltd. has announced positive phase 2 clinical trial results for HS-20089, a B7-H4-targeted antibody-drug conjugate <a href=\"https://laohu8.com/S/ADC\">$(ADC)$</a>, in patients with platinum-resistant ovarian cancer <a href=\"https://laohu8.com/S/PROC\">$(PROC)$</a>. The findings were presented in a poster session at the European Society for Medical Oncology (ESMO) 2025 Annual Meeting and will be featured in an oral presentation at the IGCS 2025 Annual Global Meeting in Cape Town, South Africa. HS-20089 (licensed to GSK as GSK5733584) demonstrated a confirmed objective response rate <a href=\"https://laohu8.com/S/ORR\">$(ORR)$</a> of 48.5%, a duration of response (DoR) of 6.8 months, a median progression-free survival (mPFS) of 6.4 months, and a median overall survival (mOS) of 14.6 months at a dose of 4.8 mg/kg. The safety profile was manageable, consistent with phase 1 data, and no new safety signals were observed. The phase 2 study included heavily pretreated PROC patients regardless of tumor B7-H4 expression. A phase 3 study of HS-20089 is currently ongoing (NCT06855069).\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Hansoh Pharmaceutical Group Co. Ltd. published the original content used to generate this news brief on October 20, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1191","symbol_name":"制药","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251020:nNDLwP66y:1","article_id":"2576019002","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2576019002","pubTimestamp":1760919442,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Hansoh Pharmaceutical Group Co., Ltd. has announced positive phase 2 clinical trial results for HS-20089, a B7-H4-targeted antibody-drug conjugate , in patients with platinum-resistant ovarian cancer . The findings were presented in a poster session at the European Society for Medical Oncology  2025 Annual Meeting and will be featured in an oral presentation at the IGCS 2025 Annual Global Meeting in Cape Town, South Africa. HS-20089  demonstrated a confirmed objective response rate  of 48.5%, a duration of response  of 6.8 months, a median progression-free survival  of 6.4 months, and a median overall survival  of 14.6 months at a dose of 4.8 mg/kg. The safety profile was manageable, consistent with phase 1 data, and no new safety signals were observed. The phase 2 study included heavily pretreated PROC patients regardless of tumor B7-H4 expression. A phase 3 study of HS-20089 is currently ongoing .","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1191":"制药","03692":"翰森制药","BK1583":"高瓴概念","BK1589":"北水核心资产"},"translate_title":"豪森制药报告HS-20089治疗铂类耐药卵巢癌的2期积极结果","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"03692":0.9},"content_text":"Hansoh Pharma Reports Positive Phase 2 Results for HS-20089 in Platinum-Resistant Ovarian Cancer\n    \n\n        Hansoh Pharmaceutical Group Co., Ltd. has announced positive phase 2 clinical trial results for HS-20089, a B7-H4-targeted antibody-drug conjugate $(ADC)$, in patients with platinum-resistant ovarian cancer $(PROC)$. The findings were presented in a poster session at the European Society for Medical Oncology (ESMO) 2025 Annual Meeting and will be featured in an oral presentation at the IGCS 2025 Annual Global Meeting in Cape Town, South Africa. HS-20089 (licensed to GSK as GSK5733584) demonstrated a confirmed objective response rate $(ORR)$ of 48.5%, a duration of response (DoR) of 6.8 months, a median progression-free survival (mPFS) of 6.4 months, and a median overall survival (mOS) of 14.6 months at a dose of 4.8 mg/kg. The safety profile was manageable, consistent with phase 1 data, and no new safety signals were observed. The phase 2 study included heavily pretreated PROC patients regardless of tumor B7-H4 expression. A phase 3 study of HS-20089 is currently ongoing (NCT06855069).\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Hansoh Pharmaceutical Group Co. Ltd. published the original content used to generate this news brief on October 20, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport,express","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}